
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CRIK CRISPR/Cas9 KO Plasmid (h) | sc-417835 | 20 µg | $397.00 | |||
CRIK HDR Plasmid (h) | sc-417835-HDR | 20 µg | $445.00 |
Citron kinase (CIT; protein CRIK) is a RhoA effector serine/threonine kinase that localizes to the cleavage furrow and midbody to coordinate actomyosin contractility during cytokinesis. Through interactions with cytoskeletal regulators and midbody scaffolds, CRIK supports contractile ring organization, abscission timing, and maintenance of genomic stability during cell division. Disruption of CIT function can lead to cytokinesis failure, multinucleation, and aneuploidy, linking this pathway to proliferative control and cancer-relevant cell cycle phenotypes. CIT is also studied in the context of neurodevelopmental processes where regulated division and cytoskeletal remodeling are critical.
CRIK CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CIT gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the CIT locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, CRIK HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined CIT target site.
When co-transfected with CRIK CRISPR/Cas9 KO Plasmid (h):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the CIT locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.